Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Arbutus Biopharma’s Earnings Outlook
Arbutus Biopharma (NASDAQ:ABUS) is set to give its latest quarterly earnings report on Thursday, 2023-05-04. Here’s what investors…
Why Arbutus Biopharma Stock Is Plunging Today
The FDA has notified via verbal communication regarding a clinical hold on Arbutus Biopharma Corporation’s (NASDAQ:ABUS) AB-101 Investigational New Drug (IND) application. …
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
A U.S. appeals court affirmed a decision to cancel an Arbutus Biopharma Corporation (NASDAQ:ABUS) patent related to a legal fight…
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Arbutus Biopharma Corporation (NASDAQ:ABUS) and its licensee Genevant Sciences have sued Pfizer Inc (NYSE:PFE) and its partner BioNTech SE (NASDAQ:BNTX) in the U.S. District Court…
HC Wainwright & Co. Maintains Buy on Arbutus Biopharma, Maintains $6 Price Target
HC Wainwright & Co. analyst Ed Arce maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $6 price target.
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Arbutus Biopharma Announces Issuance Of US Patent Related To AB-729
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has
Arbutus Biopharma Q2 EPS $(0.10) Beats $(0.13) Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from